Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb are included in this Analyst Blog.

The benchmark DAX index in Germany on Wednesday dropped by 3 percent as market turmoil triggered by U.S. tariff ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

Under the terms of the settlement, Pacira has agreed to provide Fresenius with a license to its patents required to ...

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no ...

Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...

Fresenius Kabi licensed to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. no earlier than a confidential date in 2030 ---- Fresen ...

Bernstein analyst Lisa Bedell Clive maintained a Hold rating on Fresenius SE & Co. KGaA (0OO9 – Research Report) today and set a price ...

Chronic Kidney Disease Drives Treatment Demand: In the treatment category, Chronic Kidney Disease (CKD) accounts for 80.22% of global revenue. The surge is linked to rising cases of hypertension, ...

European stocks plunged sharply, and several markets tumbled to fresh multi-month lows on Friday as US President Donald Trump ...

Fresenius Medical Care AG (ETR:FME – Get Free Report)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of €42.56 ($47.29) and ...